Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2017
At a glance
- Drugs MMR-varicella zoster virus vaccine (Primary) ; Measles mumps and rubella virus vaccine-(Priorix); Varicella zoster virus vaccine live
- Indications Chickenpox; Measles; Mumps; Rubella
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 08 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Mar 2014 According to ClinicalTrials.gov record, planned end date changed from 1 Feb 2017 to 1 Jan 2017.
- 08 Feb 2014 Results published in the Lancet.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History